{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:41Z","timestamp":1740144101040,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K12890"],"award-info":[{"award-number":["22K12890"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40264-022-01240-w","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T12:05:28Z","timestamp":1665576328000},"page":"1551-1552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comment on: \"A Disproportionality Analysis of Drug\u2013Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)\""],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9110-9604","authenticated-orcid":false,"given":"Yoshihiro","family":"Noguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"1240_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01200-4","author":"L Villa-Zapata","year":"2022","unstructured":"Villa-Zapata L, G\u00f3mez-Lumbreras A, Horn J, Tan MS, Boyce RD, Malone DC. A disproportionality analysis of drug\u2013drug interactions of tizanidine and CYP1A2 inhibitors from the FDA adverse event reporting system (FAERS). Drug Saf. 2022. https:\/\/doi.org\/10.1007\/s40264-022-01200-4.","journal-title":"Drug Saf"},{"key":"1240_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519\u201323. https:\/\/doi.org\/10.1002\/pds.1001.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1240_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/bib\/bbab347","volume":"22","author":"Y Noguchi","year":"2021","unstructured":"Noguchi Y, Tachi T, Teramachi H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform. 2021;22:347. https:\/\/doi.org\/10.1093\/bib\/bbab347.","journal-title":"Brief Bioinform."},{"key":"1240_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1046\/j.1365-2125.1999.00957.x","volume":"47","author":"EP van Puijenbroek","year":"1999","unstructured":"van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG. Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Br J Clin Pharmacol. 1999;47:689\u201393. https:\/\/doi.org\/10.1046\/j.1365-2125.1999.00957.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1240_CR5","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3389\/fphar.2019.01319","volume":"10","author":"Y Noguchi","year":"2019","unstructured":"Noguchi Y, Tachi T, Teramachi H. Review of statistical methodologies for detecting drug\u2013drug interactions using spontaneous reporting systems. Front Pharmacol. 2019;10:1319. https:\/\/doi.org\/10.3389\/fphar.2019.01319.","journal-title":"Front Pharmacol"},{"key":"1240_CR6","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/sim.3247","volume":"27","author":"GN Nor\u00e9n","year":"2008","unstructured":"Nor\u00e9n GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug-drug interaction surveillance. Stat Med. 2008;27:3057\u201370. https:\/\/doi.org\/10.1002\/sim.3247.","journal-title":"Stat Med"},{"unstructured":"Uppsala Monitoring Centre (UMC). The UMC Measures of Disproportionate Reporting. Available online: https:\/\/who-umc.org\/media\/164041\/measures-of-disproportionate-reporting_2016.pdf. Accessed 20 July, 2022.","key":"1240_CR7"},{"key":"1240_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","volume":"37","author":"Y Noguchi","year":"2020","unstructured":"Noguchi Y, Tachi T, Teramachi H. Comparison of signal detection algorithms based on frequency statistical model for drug\u2013drug interaction using spontaneous reporting systems. Pharm Res. 2020;37:86. https:\/\/doi.org\/10.1007\/s11095-020-02801-3.","journal-title":"Pharm Res"},{"key":"1240_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3820\/jjpe.14.27","volume":"14","author":"T Fujita","year":"2009","unstructured":"Fujita T. Signal detection of adverse drug reactions. Jpn J Pharmacoepidemiol. 2009;14:27\u201336. https:\/\/doi.org\/10.3820\/jjpe.14.27.","journal-title":"Jpn J Pharmacoepidemiol"},{"key":"1240_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.11256\/jjdi.21.135","volume":"21","author":"H Urushihara","year":"2019","unstructured":"Urushihara H. Basic dos and don\u2019ts in applying signal detection methods to spontaneous reporting systems databases. Jpn J Drug Inform. 2019;21:135\u201341. https:\/\/doi.org\/10.11256\/jjdi.21.135.","journal-title":"Jpn. J. Drug Inform."},{"key":"1240_CR11","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.3390\/pharmaceutics13101531","volume":"13","author":"Y Noguchi","year":"2021","unstructured":"Noguchi Y, Yoshizawa S, Aoyama K, Kubo S, Tachi T, Teramachi H. Verification of the \u201cupward variation in the reporting odds ratio scores\u201d to detect the signals of drug\u2013drug interactions. Pharmaceutics. 2021;13:1531. https:\/\/doi.org\/10.3390\/pharmaceutics13101531.","journal-title":"Pharmaceutics"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01240-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01240-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01240-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T22:13:47Z","timestamp":1669414427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01240-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1240"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01240-w","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"type":"print","value":"0114-5916"},{"type":"electronic","value":"1179-1942"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"assertion":[{"value":"5 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YN participated in the interpretation of the study and in the preparation of this letter.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contribution"}},{"value":"This reanalysis was supported by JSPS KAKENHI Grant Number 22K12890.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"YN declares that there is no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}